MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences
09 Febrero 2024 - 7:05AM
UK Regulatory
ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) -- MaxCyte, Inc.,
(NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused
company providing enabling platform technologies to advance the
discovery, development and commercialization of next-generation
cell therapeutics and innovative bioprocessing applications, today
announced that it will release financial results for the fourth
quarter and full year 2023 after the U.S. market close on Tuesday,
March 12th, 2024. Company management will host a conference call to
discuss financial results at 4:30 p.m. Eastern Time.
Earnings Conference Call
Details
Investors interested in listening to the conference call are
required to register online. It is recommended to register at least
a day in advance. A live and archived webcast of the event will be
available on the “Events” section of the MaxCyte website at
https://investors.maxcyte.com/.
Company management will also participate in the following
investor conferences:
- 11th Annual BTIG MedTech, Digital Health, Life
Science & Diagnostic Tools Conference
Tuesday, February 13th
- 44th Annual Cowen Healthcare Conference
Tuesday, March 5th at 9:10 a.m. ET
A live and archived webcast of the Cowen
presentation will be available on the “Event” section of the
MaxCyte investor relations website at
https://investors.maxcyte.com/.
About MaxCyte
At MaxCyte, we pursue cell engineering excellence to maximize the
potential of cells to improve patients’ lives. We have spent more
than 20 years honing our expertise by building best-in-class
platforms, perfecting the art of the transfection workflow, and
venturing beyond today’s processes to innovate tomorrow’s
solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed
to support the rapidly expanding cell therapy market and can be
utilized across the continuum of the high-growth cell therapy
sector, from discovery and development through commercialization of
next-generation, cell-based medicines. The ExPERT family of
products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or
disposables; and software protocols, all supported by a robust
worldwide intellectual property portfolio. By providing our
partners with the right technology, as well as scientific,
technical and regulatory support, we aim to guide them on their
journey to transform human health. Learn more at maxcyte.com and
follow us on Twitter and LinkedIn.
MaxCyte Contacts:
US IR Adviser
Gilmartin Group
David Deuchler, CFA
+1 415-937-5400
ir@maxcyte.com
US Media Relations
Spectrum Seismic Collaborative
Valerie Enes
+1 408-497-8568
venes@spectrumscience.com
Nominated Adviser and Joint Corporate
Broker
Panmure Gordon
Emma Earl / Freddy Crossley
Corporate Broking
Rupert Dearden
+44 (0)20 7886 2500
UK IR Adviser
ICR Consilium
Mary-Jane Elliott
Chris Welsh
+44 (0)203 709 5700
maxcyte@consilium-comms.com
Maxcyte (LSE:MXCN)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Maxcyte (LSE:MXCN)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024